EARS Auris Medical Holding Ltd.

2.7
+0.01  (+0%)
Previous Close 2.69
Open 2.61
Price To Book 1.61
Market Cap 6,033,715
Shares 2,234,792
Volume 43,632
Short Ratio
Av. Daily Volume 152,053

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Open label safety trial data released April 24, 2017 and May 9, 2017.
Keyzilen (AM-101) - AMPACT open-label
Acute inner ear tinnitus
Phase 3 HEALOS trial did not meet primary endpoint - November 28, 2017.
AM-111 HEALOS
Acute inner ear hearing loss
Phase 3 data released March 13, 2018 - primary endpoint not met. Noted April 25, 2019 that it intends to discuss a new Phase 2/3 trial with the FDA.
Keyzilen (AM-101)
Acute inner ear tinnitus
Phase 3 ASSENT trial terminated - November 28, 2017.
AM-111 ASSENT
Acute inner ear hearing loss
Phase 2 trial (REACH) enrollment pending funding.
AM-111 REACH
Surgery-induced hearing loss
Phase 3 trial did not meet primary endpoints
AM-101 (Keyzilen) - TACTT2
Acute inner ear tinnitus
Phase 2 interim analysis due 4Q 2019 or 1Q 2020.
AM-125
Vertigo
Phase 1b top-line data due late-3Q 2019.
AM-201
Healthy volunteers

Latest News

  1. Auris Medical Provides Business Update and Reports First Half 2019 Financial Results
  2. Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo
  3. Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced Weight Gain
  4. Auris Medical Holding Ltd Provides Corporate Update
  5. Auris Medical Holding Ltd Regains Compliance with Nasdaq Minimum Bid Price Rule
  6. Auris Medical Announces Closing of Public Offering of Common Shares
  7. Auris Medical Announces Closing of Two US Patent Acquisitions Related to the Use of Betahistine for the Treatment of Depression and ADHD
  8. Auris Medical Holding Ltd.:
  9. Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain
  10. Auris Medical Announces Reverse Stock Split
  11. Auris Medical Provides Update on Tinnitus Drug Development Strategy
  12. Buyer's Remorse? OTC Stock Zoom Technologies Zooms Higher Amid Potential Buyer Confusion
  13. Auris Medical Receives Positive Nasdaq Listing Determination
  14. Auris Medical Announces Randomization of First Dose Cohort in AM-201 Phase 1b Proof-of-Concept Study
  15. Auris Medical Announces 20-F Filing
  16. These Four Healthcare Stocks Could Test March Highs
  17. Auris: 4Q Earnings Snapshot
  18. Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
  19. Auris Medical Announces Publication of AM-111 Phase 3 Results in Peer-Reviewed Scientific Journal
  20. Auris Medical to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on Thursday, March 14, 2019